Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07394426Early Phase 1Not Yet Recruiting

A Phase I Study of PepGNP-ChikV in Healthy Volunteers

Role: lead

NCT05633446Phase 1Not Yet Recruiting

Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

Role: lead

NCT05113862Phase 1Completed

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

Role: lead

NCT04935801Phase 1Completed

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus

Role: lead

All 4 trials loaded